

Status: Currently Official on 17-Feb-2025  
Official Date: Official as of 01-May-2018  
Document Type: USP Monographs  
DocId: GUID-86A09EF6-8317-42F2-853F-7BEC550862DF\_3\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M6730\\_03\\_01](https://doi.org/10.31003/USPNF_M6730_03_01)  
DOI Ref: 3hq3g

© 2025 USPC  
Do not distribute

## Azathioprine Sodium for Injection

### DEFINITION

Azathioprine Sodium for Injection is a sterile solid prepared by the freeze-drying of an aqueous solution of Azathioprine and Sodium Hydroxide. It contains NLT 93.0% and NMT 107.0% of the labeled amount of azathioprine ( $C_9H_7N_7O_2S$ ).

### IDENTIFICATION

- A.** The principal spot from the *Sample solution* shows the same  $R_F$  value as that obtained from *Standard solution A* in the test for *Limit of Mercaptopurine*.
- B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### PROCEDURE

**Solution A:** 1.6 g/L of [sodium 1-heptanesulfonate](#) in [water](#)

**Mobile phase:** [Methanol](#) and *Solution A* (30:70). Adjust with [1 N hydrochloric acid](#) to a pH of  $3.5 \pm 0.1$ .

**Standard stock solution:** 0.5 mg/mL of [USP Azathioprine RS](#) prepared as follows. Transfer [USP Azathioprine RS](#) to a suitable volumetric flask. Add 25% of the flask volume of [methanol](#) and 1% of [ammonium hydroxide](#) to the flask, swirl, and sonicate for 2 min or until dissolved. Dilute with [methanol](#) to volume.

**Standard solution:** 0.1 mg/mL of [USP Azathioprine RS](#) in [water](#) from the *Standard stock solution*

**Sample solution:** Nominally equivalent to 0.1 mg/mL of azathioprine in [water](#) from Azathioprine Sodium for Injection

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 3.9-mm  $\times$  30-cm; 10- $\mu$ m packing [L1](#)

**Flow rate:** 1.8 mL/min

**Injection volume:** 10  $\mu$ L

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 2

**Relative standard deviation:** NMT 1.0%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of azathioprine ( $C_9H_7N_7O_2S$ ) in the portion of Azathioprine Sodium for Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of azathioprine from the *Sample solution*

$r_S$  = peak response of azathioprine from the *Standard solution*

$C_S$  = concentration of [USP Azathioprine RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of azathioprine in the *Sample solution* (mg/mL)

**Acceptance criteria:** 93.0%–107.0%

### PERFORMANCE TESTS

- UNIFORMITY OF DOSAGE UNITS (905):** Meets the requirements

### IMPURITIES

#### LIMIT OF MERCAPTOPYRINE

**Standard solution A:** 10 mg/mL of [USP Azathioprine RS](#) in [dimethylformamide](#)

**Standard solution B:** 100  $\mu$ g/mL of [USP Mercaptopurine RS](#) in [dimethylformamide](#)

**Sample solution:** 10 mg/mL of Azathioprine Sodium for Injection in [dimethylformamide](#)

#### Chromatographic system

(See [Chromatography \(621\)](#), [Thin-Layer Chromatography](#).)

**Mode:** TLC

**Adsorbent:** 0.25-mm layer of microcrystalline cellulose

**Application volume:** 5 µL for *Standard solution A* and the *Sample solution*, and 15 µL for *Standard solution B*

**Developing solvent system:** [Butyl alcohol](#) saturated with 5 N [ammonium hydroxide](#)

#### Analysis

**Samples:** *Standard solution A*, *Standard solution B*, and *Sample solution*

Proceed as directed in the chapter. Apply the *Samples* at points 2 cm from the bottom edge of a TLC plate. Allow the spots to dry, and develop the chromatogram in a suitable chamber until the solvent front has moved 15 cm from the point of application. Remove the plate, air-dry, and locate the spots by viewing under short- and long-wavelength UV light.

**Acceptance criteria:** 3.0%; any spot from the *Sample solution*, other than the principal spot, is not more intense than the spot from *Standard solution B*.

#### SPECIFIC TESTS

• **pH (791).**

**Sample solution:** The contents of one container dissolved in 10 mL of [water](#)

**Acceptance criteria:** 9.8–11.0

• **BACTERIAL ENDOTOXINS TEST (85):** It contains NMT 1.0 USP Endotoxin Unit/mg of azathioprine.

• **WATER DETERMINATION (921), Method I:** NMT 7.0%, when the *Test Preparation* is prepared as directed for a hygroscopic specimen

• **OTHER REQUIREMENTS:** It meets the requirements in [Injections and Implanted Drug Products \(1\)](#).

#### ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve as described in [Packaging and Storage Requirements \(659\)](#), [Injection Packaging](#), [Packaging for constitution](#), at controlled room temperature.

• **USP REFERENCE STANDARDS (11).**

[USP Azathioprine RS](#)

[USP Mercaptopurine RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
AZATHIOPRINE SODIUM FOR INJECTION	<a href="#">Documentary Standards Support</a>	SM32020 Small Molecules 3
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM32020 Small Molecules 3

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 41(6)

**Current DocID:** GUID-86A09EF6-8317-42F2-853F-7BEC550862DF\_3\_en-US

**Previous DocID:** GUID-86A09EF6-8317-42F2-853F-7BEC550862DF\_1\_en-US

**DOI:** [https://doi.org/10.31003/USPNE\\_M6730\\_03\\_01](https://doi.org/10.31003/USPNE_M6730_03_01)

**DOI ref:** [3hq3g](#)